Skip to content
Loading your account…

BMY BRISTOL MYERS SQUIBB CO

NYSEHealth carePharmaceutical PreparationsPrinceton, NJFY ends December 31

New 8-K: Filed an 8-K current report in the last 7 days.Profitable 4/5: Fiscal years with net income above zero, out of the last five reported.FY2025 10-K filed Feb 11, 2026 (SEC EDGAR)

FY2025 at a glance

Fundamentals from SEC filings, not quotes
Revenue
$48.2BYoYdown 0.22%ended Dec 31, 2025
Net income
$7.05B14.6% margin
Diluted EPS
$3.46YoY—
Free cash flow
$12.8B26.7% margin
Cash
$10.2BNet debt $36.9B
Total debt
$47.1BD/E 2.55×
About BRISTOL MYERS SQUIBB CO

Overview

BRISTOL MYERS SQUIBB CO (BMY) is listed on NYSE; the SEC classifies it under "Pharmaceutical Preparations".

For fiscal 2025 (ended Dec 31, 2025) it reported revenue of $48.19B, down 0.2% from fiscal 2024.

Net income was $7.05B, a net margin of 14.6%.

At fiscal year end it had total assets of $90.04B and stockholders' equity of $18.47B (20.5% of assets).

Fiscal years shown
FY2016–FY2025 (10 years)
Latest 10-K
Feb 11, 2026
Latest filing
10-QOct 29, 2026
FY2016–FY2025 · annual 10-K

Charts

Revenue and net income

Revenue and net income, fiscal years FY2016 to FY2025.
PeriodRevenueNet incomeNet margin
FY2016$19.4B$4.46B22.9%
FY2017$20.8B$1.01B4.8%
FY2018$22.6B$4.92B21.8%
FY2019$26.1B$3.44B13.2%
FY2020$42.5B-$9.02B-21.2%
FY2021$46.4B$6.99B15.1%
FY2022$46.2B$6.33B13.7%
FY2023$45B$8.03B17.8%
FY2024$48.3B-$8.95B-18.5%
FY2025$48.2B$7.05B14.6%

Gross, operating and net margin

Gross, operating and net margin, fiscal years FY2016 to FY2025.
PeriodGross marginNet margin
FY201674.5%22.9%
FY201770.8%4.8%
FY201871.0%21.8%
FY201969.1%13.2%
FY202072.3%-21.2%
FY202178.6%15.1%
FY202278.0%13.7%
FY202376.2%17.8%
FY202471.1%-18.5%
FY202571.1%14.6%

Diluted EPS

Diluted EPS, fiscal years FY2016 to FY2025.
PeriodEPS (diluted)
FY2016$2.65
FY2017$0.61
FY2018$3.01
FY2019$2.01
FY2020-$3.99
FY2021$3.12
FY2022$2.95
FY2023$3.86
FY2024-$4.41
FY2025$3.46

Free cash flow vs net income

Free cash flow vs net income, fiscal years FY2016 to FY2025.
PeriodFree cash flowNet income
FY2016$1.64B$4.46B
FY2017$4.22B$1.01B
FY2018$4.99B$4.92B
FY2019$7.23B$3.44B
FY2020$13.3B-$9.02B
FY2021$15.2B$6.99B
FY2022$11.9B$6.33B
FY2023$12.7B$8.03B
FY2024$13.9B-$8.95B
FY2025$12.8B$7.05B

Diluted shares

Diluted shares, fiscal years FY2016 to FY2025.
PeriodDiluted shares (weighted)
FY20161.68B
FY20171.65B
FY20181.64B
FY20191.71B
FY20202.26B
FY20212.25B
FY20222.15B
FY20232.08B
FY20242.03B
FY20252.04B

Cash vs total debt

Cash vs total debt, fiscal years FY2016 to FY2025.
PeriodCash & equivalentsTotal debt
FY2016$4.24B$7.46B
FY2017$5.42B$7.49B
FY2018$6.91B$8.6B
FY2019$12.3B$49.5B
FY2020$14.5B$52.7B
FY2021$14B$49.3B
FY2022$9.12B$43.2B
FY2023$11.5B$42.6B
FY2024$10.3B$51.5B
FY2025$10.2B$47.1B

Each bar is one fiscal year as reported in its 10-K; bars below the zero line are negative and gaps are years not reported. Per-share figures are as reported, not adjusted for stock splits; comparisons across a likely split are left blank.

FY2025 · 5-year trend

Ratios

Profitability

Gross margin
71.1%
Net margin
14.6%
FCF margin
26.7%
Return on equity
40.5%
Return on assets
7.7%

Growth

Growth. Compound annual growth: (end ÷ start)^(1 ÷ years) − 1, both ends positive.
Metric1y3y CAGR5y CAGR9y CAGR
Revenuedown 0.22%up 1.45%up 2.54%—
EPS (diluted)—up 5.46%—up 3.01%
Free cash flowdown 7.87%up 2.44%down 0.69%up 25.74%
Change in share count
+0.59%

Financial strength

Current ratio
1.26×
Debt / equity
2.55×
Liabilities / assets
79.4%
Net debt
$36.9B
Equity / assets
20.5%

Shareholder returns

Dividends per share
$2.49
Dividends paid
$5.05B
Buybacks
$0
Payout ratio
71.5%
Stock comp. / revenue
1.1%
Piotroski F-Score · Altman Z''-Score

Quality screens

Piotroski F-Score

8 of 9 checks passed

FY2025 vs FY2024

  • PassPositive return on assets7.6%
  • PassPositive operating cash flow$14.2B
  • PassReturn on assets improved7.6% vs -9.4%
  • PassOperating cash flow above net income15.3% vs 7.6%
  • PassLong-term debt / assets fell47.6% vs 51.4%
  • PassCurrent ratio improved1.26× vs 1.25×
  • FailNo increase in share count2.04B vs 2.03B
  • PassGross margin improved71.1% vs 71.1%
  • PassAsset turnover improved0.52× vs 0.51×

Altman Z''-Score

Needs current assets and liabilities, retained earnings, operating income, total assets, liabilities and equity from the latest 10-K.

Screening heuristic, not a recommendation. Per-share figures are as reported, not adjusted for stock splits; comparisons across a likely split are left blank.

Last 10 fiscal years · newest first

Financial statements

USD millions, except per-share figures (USD). Share counts in millions.

Income statement

Income statement. USD millions, except per-share figures (USD). Share counts in millions.
MetricFY2025Dec 31, 2025FY2024Dec 31, 2024FY2023Dec 31, 2023FY2022Dec 31, 2022FY2021Dec 31, 2021FY2020Dec 31, 2020FY2019Dec 31, 2019FY2018Dec 31, 2018FY2017Dec 31, 2017FY2016Dec 31, 2016
Revenue48,19448,30045,00646,15946,38542,51826,14522,56120,77619,427
YoY (Revenue)-0.22%+7.32%-2.50%-0.49%+9.09%+62.62%+15.89%—+6.94%—
Gross profit34,25834,33234,31336,02236,44530,74518,06716,01414,71014,481
Research & development9,95111,1599,2999,50911,35411,1436,1486,3456,4114,940
Selling, general & admin.7,2678,4147,7727,8147,6907,6614,8714,5514,6874,911
Interest expense1,8911,9471,1661,2321,3341,420656183196167
Pretax income9,328-8,3798,4407,7138,098-6,8714,9755,9685,1315,915
Income tax2,2725544001,3681,0842,1241,5151,0214,1561,408
Net income7,054-8,9488,0256,3276,994-9,0153,4394,9201,0074,457
YoY (Net income)—-211.50%+26.84%-9.54%—-362.14%-30.10%+388.58%-77.41%—
EPS (basic)3.47-4.413.882.973.15-3.992.023.010.612.67
EPS (diluted)3.46-4.413.862.953.12-3.992.013.010.612.65
YoY (EPS (diluted))—-214.25%+30.85%-5.45%—-298.51%-33.22%+393.44%-76.98%—
Diluted shares (weighted)2,0392,0272,0782,1462,2452,2581,7121,6371,6521,680

Balance sheet

Balance sheet. USD millions, except per-share figures (USD). Share counts in millions.
MetricFY2025Dec 31, 2025FY2024Dec 31, 2024FY2023Dec 31, 2023FY2022Dec 31, 2022FY2021Dec 31, 2021FY2020Dec 31, 2020FY2019Dec 31, 2019FY2018Dec 31, 2018FY2017Dec 31, 2017FY2016Dec 31, 2016
Cash & equivalents10,20910,34611,4649,12313,97914,54612,3466,9115,4214,237
Receivables9,5929,0128,8828,1517,9797,2196,4764,6364,3473,774
Inventory2,6902,5572,6622,3392,0952,0744,2931,1951,1661,241
Current assets29,39029,78031,77027,27333,26230,19229,35417,16014,85413,704
Goodwill21,75421,71921,16921,14920,50220,54722,4886,5386,8636,875
Intangible assets19,10323,30727,07235,85942,52753,24363,9691,0911,2101,385
Total assets90,03892,60395,15996,820109,314118,481129,94434,98633,55133,707
Current liabilities23,41723,77422,26221,89021,86819,08018,30410,6549,5638,841
Short-term debt4,2383,8745,9928,1619,7124,3406,1092,9525121,741
Long-term debt42,85047,60336,65335,05639,60548,33643,3875,6466,9755,716
Total liabilities71,53376,21565,67465,70273,30880,59978,24620,85921,70417,360
Retained earnings16,89614,91228,76625,50323,82021,28134,47434,06531,16033,513
Stockholders' equity18,47316,33529,43031,06135,94637,82251,59814,03111,74116,177
Shares outstanding2,0362,0292,0222,0992,1802,2402,2581,6331,6331,673

Cash flow

Cash flow. USD millions, except per-share figures (USD). Share counts in millions.
MetricFY2025Dec 31, 2025FY2024Dec 31, 2024FY2023Dec 31, 2023FY2022Dec 31, 2022FY2021Dec 31, 2021FY2020Dec 31, 2020FY2019Dec 31, 2019FY2018Dec 31, 2018FY2017Dec 31, 2017FY2016Dec 31, 2016
Operating cash flow14,15615,19013,86013,06616,20714,0528,0675,9405,2752,850
Capital expenditures1,3111,2481,2091,1189737538369511,0551,215
Free cash flow12,84513,94212,65111,94815,23413,2997,2314,9894,2201,635
YoY (Free cash flow)-7.87%+10.20%+5.88%-21.57%+14.55%+83.92%+44.94%+18.22%+158.10%—
Depreciation & amortization4,0119,6009,76010,27610,68610,3801,746637789382
Stock-based compensation553507518457583779441221199205
Share repurchases005,1558,0016,2871,5467,3003202,469231
Dividends paid5,0454,8634,7444,6344,3964,0752,6792,6132,5772,547
Dividends per share2.492.422.312.192.011.841.681.611.571.53
Key financials (annual, 10-K)

Values as reported in each fiscal year's Form 10-K (XBRL data on SEC EDGAR); growth and ratios are computed from those values. Revenue is the total revenue figure the company tagged (omitted when the only figure tagged is evidently partial, e.g. below net income); growth is only shown between consecutive ~12-month fiscal years reported with the same revenue measure. Per-share figures and share counts are as reported and not adjusted for later stock splits. — = not reported.

FY2025 · per diluted weighted share

Per share and valuation context

EPS (diluted)
$3.46
Revenue per share
$23.64
FCF per share
$6.30
Book value per share
$9.06
Tangible book per share
-$10.98
Cash per share
$5.01
Dividends per share
$2.49
Public floatas of Jun 30, 2025
$94.2B

Price ratios need a live quote. This page shows no stock prices. Per-share figures are as reported, not adjusted for stock splits; comparisons across a likely split are left blank.

Price ratio calculator

Type a share price to compute ratios from the latest 10-K figures. Nothing is stored or sent. (FY2025)

Market capPrice × diluted weighted shares
—
P/EPrice ÷ diluted EPS
—
P/BPrice ÷ book value per share
—
P/SPrice ÷ revenue per share
—
P/FCFPrice ÷ FCF per share
—
Dividend yieldDividends per share ÷ price
—
SEC EDGAR

Filing timeline

  1. 10-QNew
    Quarterly report· Sep 30, 2026(SEC EDGAR)
  2. 8-KNew
    Current report· Oct 29, 2026(SEC EDGAR)
    • 2.02Results of operations
    • 7.01Regulation FD disclosure
    • 9.01Financial statements and exhibits
  3. 10-Q
    Quarterly report· Jun 30, 2026(SEC EDGAR)
  4. 8-K
    Current report· Jul 30, 2026(SEC EDGAR)
    • 2.02Results of operations
    • 7.01Regulation FD disclosure
    • 9.01Financial statements and exhibits
  5. 8-K
    Current report· May 5, 2026(SEC EDGAR)
    • 5.07Shareholder vote results
  6. 10-Q
    Quarterly report· Mar 31, 2026(SEC EDGAR)
  7. 8-K
    Current report· Apr 30, 2026(SEC EDGAR)
    • 2.02Results of operations
    • 7.01Regulation FD disclosure
    • 9.01Financial statements and exhibits
  8. DEF 14A
    Proxy statement· May 5, 2026(SEC EDGAR)
  9. 10-K
    Annual report· Dec 31, 2025(SEC EDGAR)
  10. 8-K
    Current report· Feb 5, 2026(SEC EDGAR)
    • 2.02Results of operations
    • 7.01Regulation FD disclosure
    • 9.01Financial statements and exhibits
All filings on SEC EDGAR
SIC 2834 · Pharmaceutical Preparations

Peers (same SIC code)

Peers (same SIC code)
TickerRevenue (FY)YoYNet marginROEF-Score5y revenue
JNJJOHNSON & JOHNSON$94.2B—28.5%———
LLYELI LILLY & Co$65.2B—31.7%———
MRKMerck & Co., Inc.$65B—28.1%———
ABBVAbbVie Inc.$61.2B—6.9%———
BMYBRISTOL MYERS SQUIBB CO (This company)$48.2Bdown 0.22%14.6%40.5%8/9
ABTABBOTT LABORATORIES$44.3Bup 5.67%14.7%13.1%6/9
NVSNOVARTIS AG——————
AZNASTRAZENECA PLC——————
NVONOVO NORDISK A S——————
Peer median$65Bup 5.67%28.1%13.1%6/9—

Companies with the same 4-digit SIC code, ordered by latest revenue. The median excludes this company. — = not reported or not computable.

Frequently asked questions

What does BRISTOL MYERS SQUIBB CO do?

The SEC classifies BRISTOL MYERS SQUIBB CO under Standard Industrial Classification (SIC) code 2834, "Pharmaceutical Preparations". It is headquartered in Princeton, NJ. It is incorporated in DE. In fiscal 2025 it reported revenue of $48.19B and net income of $7.05B in its annual 10-K report.

What was BRISTOL MYERS SQUIBB CO's revenue in 2025?

BRISTOL MYERS SQUIBB CO reported revenue of $48.19B for fiscal 2025, which ended Dec 31, 2025, down 0.2% from $48.3B in fiscal 2024, according to its annual 10-K report filed with the SEC on Feb 11, 2026.

What was BRISTOL MYERS SQUIBB CO's net income in 2025?

BRISTOL MYERS SQUIBB CO reported net income of $7.05B for fiscal 2025, a net margin of 14.6% of revenue.

Where is BRISTOL MYERS SQUIBB CO listed?

According to the SEC, BRISTOL MYERS SQUIBB CO's ticker BMY is listed on NYSE. The SEC also lists the ticker CELG-RI for the company.

When does BRISTOL MYERS SQUIBB CO's fiscal year end?

According to the SEC, BRISTOL MYERS SQUIBB CO's fiscal year ends on December 31; its latest reported fiscal year (2025) ended Dec 31, 2025.

Source: SEC EDGAR · Last updated:

Ver en español

Not investment advice: This page shows financial data that companies reported to the US Securities and Exchange Commission, for information only. It is not investment advice or a recommendation to buy or sell any security, and it shows no stock prices. Data may be incomplete, restated or out of date — check the original filings on SEC EDGAR before making decisions.